Skip to content

A study to find the efficacy and safety of BioMinox A DD for the treatment of dandruff and hair loss

An open label clinical trial to study the efficacy and safety of BioMinox A DD for the treatment of dandruff and hair loss

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/08/002869
Enrollment
15
Registered
2012-08-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Biominox A DD Shampoo: Biominox A DD Shampoo BioMinox consists of Aloe Vera, Coco glucoside, Glycolic Acid, lauryl glucoside, Piroctone olamine and salicylic acid BioMinox A DD is to b

Sponsors

Sante Mernaud Pharmaceuticals Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Males and females of age group 18-50 years • Subjects who are suffering from mild to moderate dandruff and hair loss. • Subjects who are willing to give written informed consent

Exclusion criteria

Exclusion criteria: • Any dermatological condition of the scalp other than hair loss and /or dandruff. • Any prior hair growth procedures (e.g., hair transplant or laser) • History of alcohol or drug addiction • History of skin allergy • Any active skin infection in the scalp area or scarring in the target area. • Subject had ever received radiation therapy to the scalp, or had chemotherapy within the past year. • Subject had participated in any investigational study within the 30 days prior to trial. • A history or the presence of any serious and/or chronic medical condition(s) including psychiatric illnesses] which, in the opinion of the investigator, may cause harm to the individual and/or compromise/confound the study results. • Subjects unwilling or unable to comply with the study procedures

Design outcomes

Primary

MeasureTime frame
â?¢ Reduction in dandruff score [Baseline and visit 4] â?¢ Change in investigator global assessment for hair loss and dandruff (Mild-1, Moderate-2 and severe-3) [Baseline and visit 4] â?¢ Changes in hair objective hair assessments for hair loss- Hair density and Comb test [Baseline and visit 4]. Timepoint: Baseline and visit 4

Secondary

MeasureTime frame
â?¢ Subjective Assessment by patient using questionnaire [Baseline and visit 4] â?¢ Assessment of adverse events in all visits Timepoint: Baseline and visit 4

Countries

India

Contacts

Public ContactVikram Baburao

Sante Mernaud Pharmaceuticals

ingalagi@santemernaud.com9886014528

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026